This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Dr. Berman Replies

Robert M. Berman, MD

Published: June 30, 2008

Article Abstract

Letter to the Editor

Sir: We thank Drs. Rakofsky and Ghaemi for their inquiry onthe recent study published by my colleagues and me. This articlereports the first of 2 studies (see also Marcus et al.) inwhich we present the efficacy and safety of aripiprazole as adjunctivetreatment to standard antidepressant therapy (ADT) inpatients with major depressive disorder who have had an inadequateresponse to ADTs. This study showed that adjunctivearipiprazole, compared with adjunctive placebo, significantlyimproved depressive symptoms as measured by the change inthe Montgomery-Asberg Depression Rating Scale total scorefrom baseline, the primary outcome measure.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 69

Quick Links: Psychiatry

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...

Read More...